Genetic Loss-of-Function Studies of SETD2 in Kidney Tumorigenesis
SETD2 在肾肿瘤发生中的遗传功能丧失研究
基本信息
- 批准号:10392931
- 负责人:
- 金额:$ 52.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-05-07 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:ATAC-seqAcute leukemiaAddressAffectApplications GrantsBody of uterusCell DeathCell LineChromatinChromosomesClear CellClear cell renal cell carcinomaColorectal AdenocarcinomaDataData SetDevelopmentDiseaseDistant MetastasisEndometrial CarcinomaEpigenetic ProcessEpithelialEpithelial CellsEventFRAP1 geneGastric AdenocarcinomaGene ExpressionGeneticGenetic TranscriptionGenetic studyGenetically Engineered MouseGenomicsGoalsHumanHyperactivityKidneyKidney NeoplasmsKnockout MiceLung AdenocarcinomaMalignant NeoplasmsMediatingMethodologyModelingMolecularMusMutateMutationNeoplasm MetastasisNonmetastaticOncogenesOncogenicOxidative PhosphorylationPIK3CA genePathway interactionsPatientsPhysiologicalPre-Clinical ModelPrimary carcinoma of the liver cellsRNA Polymerase IIRas/RafRenal carcinomaReportingRoleSignal TransductionThe Cancer Genome AtlasTransplantationTubular formationTumor Suppressor Proteinsbasebladder transitional cell carcinomacancer genomecancer genomicsconditional knockoutdriver mutationexperiencefatty acid metabolismgenome sequencinggenomic datakidney cortexloss of functionmelanomamouse geneticsmouse modelmutantnovelnovel therapeuticsrecruitrestorationtranscriptome sequencingtumortumor initiationtumorigenesis
项目摘要
Recent large-scale cancer genome sequencing studies have uncovered epigenetic regulators as a new major
class of cancer genes. SETD2 is one such example. SETD2 encodes a non-redundant H3K36
trimethyltransferase and is frequently mutated in a wide variety of human cancers. Based on TCGA datasets,
SETD2 is mutated in 13% of clear cell renal cell carcinoma (ccRCC), 8.9% of uterine corpus endometrial
carcinoma, 8.7% of lung adenocarcinoma, 6.9% of bladder urothelial carcinoma, 5.5% of stomach
adenocarcinoma, 5.4% of colorectal adenocarcinoma, 5.2% of melanoma, 4.6 % of hepatocellular carcinoma,
etc. The majority of SETD2 mutations identified in ccRCC and lung adenocarcinoma are truncating mutations
located upstream of the SRI domain that mediates the interaction of SETD2 with RNA polymerase II. Notably,
chromosome 3p where SETD2 resides is commonly deleted in both ccRCC and lung adenocarcinoma.
Altogether, these cancer genomics data strongly support a tumor suppressor role of SETD2. However, the
tumor suppressor function of SETD2 has not been fully established and how SETD2 loss-of-function promotes
tumorigenesis remains unclear. Herein, we have generated conditional Setd2 knockout mice to address the
tumor suppressor function/mechanisms of SETD2 in kidney cancer. Notably, SETD2 mutations often co-occur
with other well-established driver mutations, such as VHL and PBRM1 in ccRCC, MLL-fusions in acute
leukemia, and mutations activating the RTK/RAS/RAF pathway in lung adenocarcinomas, suggesting that
SETD2 loss probably cooperates with these driver mutations to promote tumorigenesis. Among cancers in
which SETD2 mutations have been reported, ccRCC shows the highest mutation rate. Although ccRCC has
long been recognized as a VHL loss-driven disease in which VHL is mutated or silenced in up to 80-90% of
ccRCC, deletion of Vhl alone is insufficient to induce kidney cancer in mice, indicating that additional genetic
event(s) is required to cooperate with VHL loss for kidney tumorigenesis. Here, we hypothesize that VHL loss
and SETD2 loss will cooperate to promote ccRCC development, which will be interrogated using genetically
engineered mouse models. Furthermore, our genomic studies indicate that SETD2 mutations are associated
with ccRCC progression and metastasis. We plan to establish patient-derived preclinical models of metastatic
SETD2 mutant ccRCC to investigate the role of SETD2 loss in promoting tumor metastasis. Our goals are to
establish physiological preclinical models of ccRCC based on human cancer genomics, to provide mechanistic
understanding of how dysregulated epigenetics conferred by SETD2 loss promotes tumor initiation and
metastasis, and to discover novel therapeutic vulnerabilities associated with loss of SETD2.
近年来,大规模的癌症基因组测序研究揭示了表观遗传调控因子作为一个新的专业
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Elective Cytoreductive Nephrectomy After Checkpoint Inhibitor Immunotherapy in Patients With Initially Unresectable Metastatic Clear Cell Renal Cell Carcinoma.
- DOI:10.1016/j.clgc.2020.04.002
- 发表时间:2020-10
- 期刊:
- 影响因子:3.2
- 作者:Reimers MA;Figenshau RS;Kim EH;Tucker J;Kasten N;Khan AS;Hanneken JM;Smith ZL;Hsieh JJ
- 通讯作者:Hsieh JJ
Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy.
- DOI:10.1002/ctm2.1267
- 发表时间:2023-05
- 期刊:
- 影响因子:10.6
- 作者:
- 通讯作者:
SETD2 regulates chromatin accessibility and transcription to suppress lung tumorigenesis.
- DOI:10.1172/jci.insight.154120
- 发表时间:2023-02-22
- 期刊:
- 影响因子:8
- 作者:Xie, Yuchen;Sahin, Merve;Wakamatsu, Toru;Inoue-Yamauchi, Akane;Zhao, Wanming;Han, Song;Nargund, Amrita M.;Yang, Shaoyuan;Lyu, Yang;Hsieh, James J.;Leslie, Christina S.;Cheng, Emily H.
- 通讯作者:Cheng, Emily H.
The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age.
- DOI:10.1016/j.semnephrol.2019.12.004
- 发表时间:2020-01
- 期刊:
- 影响因子:3.3
- 作者:Huang JJ;Hsieh JJ
- 通讯作者:Hsieh JJ
Linking Binary Gene Relationships to Drivers of Renal Cell Carcinoma Reveals Convergent Function in Alternate Tumor Progression Paths
将二元基因关系与肾细胞癌的驱动因素联系起来揭示了替代肿瘤进展路径中的趋同功能
- DOI:10.1038/s41598-019-39875-y
- 发表时间:2019
- 期刊:
- 影响因子:4.6
- 作者:Poehlman, William L.;Hsieh, James J.;Feltus, F. Alex
- 通讯作者:Feltus, F. Alex
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
EMILY H CHENG其他文献
EMILY H CHENG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('EMILY H CHENG', 18)}}的其他基金
Project III: Engineering immunogenic cell death in melanoma and renal cell carcinoma.
项目 III:工程化黑色素瘤和肾细胞癌中的免疫原性细胞死亡。
- 批准号:
10525194 - 财政年份:2022
- 资助金额:
$ 52.18万 - 项目类别:
Project III: Engineering immunogenic cell death in melanoma and renal cell carcinoma.
项目 III:工程化黑色素瘤和肾细胞癌中的免疫原性细胞死亡。
- 批准号:
10705788 - 财政年份:2022
- 资助金额:
$ 52.18万 - 项目类别:
Characterizing and Targeting BAX- and BAK-Dependent Cell Death in Cancer
癌症中 BAX 和 BAK 依赖性细胞死亡的表征和靶向
- 批准号:
10375572 - 财政年份:2021
- 资助金额:
$ 52.18万 - 项目类别:
Characterizing and Targeting BAX- and BAK-Dependent Cell Death in Cancer
癌症中 BAX 和 BAK 依赖性细胞死亡的表征和靶向
- 批准号:
10211264 - 财政年份:2021
- 资助金额:
$ 52.18万 - 项目类别:
Characterizing and Targeting BAX- and BAK-Dependent Cell Death in Cancer
癌症中 BAX 和 BAK 依赖性细胞死亡的表征和靶向
- 批准号:
10621724 - 财政年份:2021
- 资助金额:
$ 52.18万 - 项目类别:
Genetic Loss-of-Function Studies of SETD2 in Kidney Tumorigenesis
SETD2 在肾肿瘤发生中的遗传功能丧失研究
- 批准号:
9916771 - 财政年份:2018
- 资助金额:
$ 52.18万 - 项目类别:
相似海外基金
Targeting Menin in Acute Leukemia with Upregulated HOX Genes
通过上调 HOX 基因靶向急性白血病中的 Menin
- 批准号:
10655162 - 财政年份:2023
- 资助金额:
$ 52.18万 - 项目类别:
Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing
利用 CRISPR 富集和实时长读长测序进行快速急性白血病基因组分析
- 批准号:
10651543 - 财政年份:2023
- 资助金额:
$ 52.18万 - 项目类别:
Experimental and preclinical modeling of NUP98-rearranged acute leukemia
NUP98重排急性白血病的实验和临床前模型
- 批准号:
10829603 - 财政年份:2023
- 资助金额:
$ 52.18万 - 项目类别:
Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing
利用 CRISPR 富集和实时长读长测序进行快速急性白血病基因组分析
- 批准号:
10839678 - 财政年份:2023
- 资助金额:
$ 52.18万 - 项目类别:
A Systems Epidemiology Approach for Predicting Methotrexate Neurotoxicity in Pediatric Acute Leukemia
预测儿童急性白血病甲氨蝶呤神经毒性的系统流行病学方法
- 批准号:
10655716 - 财政年份:2023
- 资助金额:
$ 52.18万 - 项目类别:
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
抗CD25放射免疫治疗和全骨髓照射治疗复发难治性急性白血病
- 批准号:
10435886 - 财政年份:2022
- 资助金额:
$ 52.18万 - 项目类别:
mRNA stability and its impact on hematopoiesis and acute leukemia
mRNA稳定性及其对造血和急性白血病的影响
- 批准号:
10339742 - 财政年份:2022
- 资助金额:
$ 52.18万 - 项目类别:
Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
通过多层次干预使急性白血病临床试验招募多样化
- 批准号:
10505579 - 财政年份:2022
- 资助金额:
$ 52.18万 - 项目类别:
Clonal dynamics and chemoresistance mechanisms of minimal residual disease in acute leukemia
急性白血病微小残留病的克隆动力学和化疗耐药机制
- 批准号:
10351765 - 财政年份:2022
- 资助金额:
$ 52.18万 - 项目类别:
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
抗CD25放射免疫治疗和全骨髓照射治疗复发难治性急性白血病
- 批准号:
10576955 - 财政年份:2022
- 资助金额:
$ 52.18万 - 项目类别:














{{item.name}}会员




